OC-66: EVALUATION OF A COMPLEMENTARY THERAPY WITH INMUNOMODULATOR BIOMODULINA T IN PATIENTS WITH NEOPLASIC DISEASE

J Pharm Pharmacogn Res 3(suppl. 1): S69, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Oral Communication

OC-66: EVALUATION OF A COMPLEMENTARY THERAPY WITH INMUNOMODULATOR BIOMODULINA T IN PATIENTS WITH NEOPLASIC DISEASE

Aznar-García E1, Súarez-Fundora S1, Battista-Speranza G2, Perea Y3, Rodriguez-Chávez S1.

1Clinical and Health Registry, National Center of Bioproducts (BioCen), Bejucal, Mayabeque, Cuba. E-mail: eaznar@biocen.cu, eaznar@infomed.sld.cu
2Day Oncologic Hospital G. B. Grassi Ostia.
3Production Plant. National Center of Bioproducts (BioCen), Bejucal, Mayabeque, Cuba.

 

Introduction: In the neoplasic disease the immune system recognizing an immunodeficiency state. Therefore the use of immunomodulators in these patients has become one of the most important therapies. Biomodulina T (BMT) is a natural product, obtained from bovine thymic fraction and produced in BioCen. The polypeptide composition of BMT could permit its use as immunomodulator and was demonstrate in geriatric patients. In these studies, the aim was to evaluate immunomodulator effect to BMT in the neoplasic patients. Material and Methods: Were studied 22 neoplasics patients.The protocol was approved by the Ethical Committee of the hospital. The patients was treated with chemotherapy (QT) and radiotherapy (RT) and divided in two groups: Group 1 treated with QT/RT and (BMT) (3 mg) by intramuscular rout, one daily dose. Group 2 untreated BMT. The studied evaluate the Clinical analyses, the leukocyte count, total lymphocytes and CD3;CD4/CD8, CD19, Interferon gamma. We compared the results in both groups after 3, 6 and 12 months of treatment. Results: The Group 1 (received BMT) was an increase in the number of total leukocytes in the 54.5 % after the 6 months and 86.3 % (19) after 12 months. In these patients, the CD4/CD8 demostrated an increased in 17 patients (77.2 %) after 6 months in the Group 1 (BMT use) and 18 patients (81.8 %) after 12 month of BMT treated. The CD19 lymphocytes demonstrated an increase after 6 months, in 20 patients (91%) and, after 12 months. Group 2 that did not showed any change in immunological parameters. Clinical evaluation demonstrated an improvement the quality of life in the patients G1. Conclusions: The use of BMT associated with QT/RT was capable of restoring and keeping the immune response and reducing the immunosupressor and collateral damages induced by antineoplastic therapy without RAM.

 

Citation Format: Aznar-García E, Súarez-Fundora S, Battista-Speranza G, Perea Y, Rodriguez-Chávez S (2015) Evaluation of a complementary therapy with inmunomodulator biomodulina T in patients with neoplasic disease. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S69. Abstract nr OC-66.